Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01132053
Other study ID # 2004P000089
Secondary ID NS 047029
Status Completed
Phase
First received
Last updated
Start date June 2004
Est. completion date December 2018

Study information

Verified date August 2023
Source Beth Israel Deaconess Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a continuation of our previous studies on Progressive Multifocal Leukoencephalopathy (PML). We will focus on the role of inflammation in PML, and define prognostic markers of disease evolution.


Description:

To determine precisely what are the host or viral factors that may predict a favorable outcome for PML patients and the role of inflammation in preventing JCV from causing brain disease. One of the goals of this study is to help establish non-invasive markers of PML evolution by studying the brain metabolism in PML lesions using Magnetic Resonance Imaging (MRI), Magnetic Spectroscopy (MRS) and other advanced imaging modalities.


Recruitment information / eligibility

Status Completed
Enrollment 126
Est. completion date December 2018
Est. primary completion date September 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - PML patients of 18 years of age or older will be included in this study. Exclusion Criteria: 1. Presence of opportunistic brain lesions other than PML. ( e.g., toxoplasmosis, lymphoma) 2. Presence of confounding neurological disorder such as brain neoplasm etc. In addition patients with a contraindication to MRI examination will be excluded from study. Contraindications to the MRI examination include: 1. Medically unstable or hematological, renal, or hepatic dysfunction. 2. Cardiac pacemaker 3. Internal clips, 4. Metal implants, or external clips with 10 mm of the head. 5. Metal in the eyes. 6. Pregnant 7. Claustrophobia

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Beth Israel Deaconess Medical Center National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT02004444 - JC Virus Reactivation in Multiple Sclerosis N/A
Terminated NCT01211639 - Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy N/A
Recruiting NCT05849467 - Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy Phase 1
Recruiting NCT01730131 - Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Recruiting NCT04781309 - NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy Early Phase 1
Completed NCT02694783 - Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells Early Phase 1
Completed NCT03399981 - Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
Terminated NCT00746941 - Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) Phase 1/Phase 2
Completed NCT02895581 - Retrospective Study of the Survival of Patients Suffering From Hiv-related Progressive Multifocal Leukoencephalopathy N/A
Recruiting NCT04453917 - Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy N/A
Not yet recruiting NCT05541549 - A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML Phase 2
Recruiting NCT04091932 - Treatment of PD-1 Inhibitor in AIDS-associated PML Phase 2
Not yet recruiting NCT06276504 - Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection Phase 2/Phase 3